Adma Biologics Inc. (ADMA) Trading Down 4%
Adma Biologics Inc. (NASDAQ:ADMA) shares traded down 4% on Monday . The stock traded as low as $6.49 and last traded at $6.52, with a volume of 56,526 shares changing hands. The stock had previously closed at $6.79.
Separately, Maxim Group reissued a “buy” rating and set a $24.00 price target on shares of Adma Biologics in a research report on Thursday, March 24th.
The company’s 50-day moving average price is $6.97 and its 200-day moving average price is $6.40. The company’s market cap is $83.76 million.
Adma Biologics (NASDAQ:ADMA) last released its earnings results on Friday, May 13th. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by $0.06. Equities analysts forecast that Adma Biologics Inc. will post ($1.03) EPS for the current fiscal year.
In other Adma Biologics news, Director Jerrold B. Grossman bought 45,769 shares of Adma Biologics stock in a transaction on Tuesday, May 3rd. The stock was bought at an average price of $6.50 per share, with a total value of $297,498.50. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Adam S. Grossman bought 200,000 shares of Adma Biologics stock in a transaction on Tuesday, May 3rd. The stock was acquired at an average cost of $6.50 per share, with a total value of $1,300,000.00. The disclosure for this purchase can be found here.
ADMA Biologics, Inc is a biopharmaceutical company that develops and manufactures specialty plasma-based biologics for the treatment and prevention of certain infectious diseases. The company’s targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.